In the past, genetic testing was based only on the high-penetrance genes such as BRCA1 and BRCA2, which account for around 12 to 15% of ovarian cancers (OC) and 3 to 5% of breast cancers (BC) in most populations worldwide [4]. This evidence concerns the gene BRCA1 and ovarian carcinoma.